Chengdu Ucello’s UC101 CAR‑T Gains NMPA Approval
China‑based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for...
Drug
Daiichi Sankyo’s Enhertu Submitted for Priority Review in China for HER2-Positive Breast Cancer
On August 22, 2025, Daiichi Sankyo (TYO: 4568) submitted a marketing authorization application for Enhertu...
Yantai Dongcheng’s 225Ac-LNC1011 Injection Gains FDA Approval for Prostate Cancer Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675), a China-based company, announced that its 225Ac-LNC1011...
Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) , a China-based pharmaceutical company, announced on August 21,...
Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection
Zhejiang Medicine Co., Ltd. (SHA: 600216), a China-based pharmaceutical company, announced that it has received...
Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...
Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Saniona (STO: SANION) announced today that they have entered...
Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...
InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors
China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...
Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards
On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...
Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction
Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...
Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors
On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...
Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC
On August 20, 2025, Sino Biopharmaceutical Limited (HKG: 1177) announced that its selective HER2 tyrosine...
Chongqing Genrix Bio Pharmaceutical’s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802...
Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...
Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that LM-302, an innovative antibody-drug conjugate (ADC) developed...
China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) and its subsidiary Gensun Biopharma Inc. announced...
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, announced that its novel...
Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient...